MDXG MIMEDX GROUP, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1376339 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.8%
TTM net income YoY-147.0%
TTM EPS YoY-148.1%
Revenue 3-yr CAGR-0.6%
Net income 3-yr CAGR—
Margins
Gross margin77.3%
Operating margin-8.3%
Net margin-6.3%
FCF margin—
EBITDA margin-3.5%
Returns
ROE-8.5%
ROA-6.6%
ROIC (approx.)-19.3%
Asset turnover1.04x
Leverage & solvency
Liabilities / assets20.2%
Debt / equity0.00x
Current ratio4.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.08x
Accruals ratio-13.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $418.63M | $348.88M |
| Cost of revenue | $73.01M | $60.07M |
| Gross profit | $345.62M | $288.81M |
| R&D expense | $15.10M | $12.34M |
| SG&A expense | $266.19M | $225.09M |
| Operating income | $63.89M | $58.87M |
| Interest expense | $1.78M | $3.94M |
| Pretax income | $66.26M | $57.29M |
| Income tax | $17.68M | $15.30M |
| Net income | $48.58M | $42.42M |
| EBITDA | $78.77M | $64.91M |
| EPS (basic) | 0.33 | 0.29 |
| EPS (diluted) | 0.32 | 0.28 |
| Weighted avg. shares (diluted) | 149.72M | 149.05M |
| Balance sheet | ||
| Cash & equivalents | $166.12M | $104.42M |
| Receivables | $75.71M | $55.83M |
| Inventory | $25.34M | $23.81M |
| Current assets | $277.47M | $191.89M |
| PP&E, net | $4.71M | $5.94M |
| Goodwill | $19.44M | $19.44M |
| Intangibles | $14.16M | $11.63M |
| Total assets | $342.65M | $263.92M |
| Current liabilities | $64.27M | $45.59M |
| Short-term debt | $1.50M | $1.00M |
| Long-term debt | $16.47M | $17.83M |
| Total debt | $17.97M | $18.83M |
| Total liabilities | $86.11M | $70.81M |
| Shareholders' equity | $256.55M | $193.11M |
| Net debt | -$148.15M | -$85.59M |
| Shares outstanding | 148.09M | 146.93M |
| Cash flow statement | ||
| Operating cash flow | $74.00M | $66.20M |
| Investing cash flow | -$6.89M | -$9.58M |
| Financing cash flow | -$5.41M | -$34.20M |
| Depreciation & amortization | $14.88M | $6.04M |
| Stock-based compensation | $16.40M | $16.93M |
| Share buybacks | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.